The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53

Oncogene

Volumn 34, Issue 25, 2015, Pages 3336-3348

  Thomas, A ^a   Perry, T ^a   Berhane, S ^a   Oldreive, C ^a   Zlatanou, A ^a   Williams, L R ^a   Weston, V J ^a   Stankovic, T ^a   Kearns, P ^a   Pors, K ^b   Grand, R J ^a   Stewart, G S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCHEMIX; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; ATM PROTEIN; DNA TOPOISOMERASE INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL DEATH; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG MECHANISM; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; G2 PHASE CELL CYCLE CHECKPOINT; GENETICS; LEUKEMIA, LYMPHOID; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTHRAQUINONES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL DEATH; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LEUKEMIA, LYMPHOID; M PHASE CELL CYCLE CHECKPOINTS; MICE; TOPOISOMERASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84931564622     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.266     Document Type: Article

References (37)

1. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009; 9: 338-350.
2. Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 2009; 9: 327-337.
3. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 2003; 99: 167-181.
4. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 2013; 8: 82-95.
5. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002; 3: 430-440.
6. Beeharry N, Rattner JB, Caviston JP, Yen T. Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override. Cell Cycle 2013; 12: 1588-1597.
7. Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, Khanna KK. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene 2010; 29: 6085-6098.
8. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-292.
9. Pors K, Paniwnyk Z, Teesdale-Spittle P, Plumb JA, Willmore E, Austin CA et al. Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer. Mol Cancer Ther 2003; 2: 607-610.
10. Pors K, Paniwnyk Z, Ruparelia KC, Teesdale-Spittle PH, Hartley JA, Kelland LR et al. Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells. J Med Chem 2004; 47: 1856-1859.
11. Abdallah QM, Phillips RM, Johansson F, Helleday T, Cosentino L, Abdel-Rahman H et al. Minor structural modifications to alchemix influence mechanism of action and pharmacological activity. Biochem Pharmacol 2012; 83: 1514-1522.
12. Caldecott K, Banks G, Jeggo P. DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II. Cancer Res 1990; 50: 5778-5783.
13. Forrest RA, Swift LP, Evison BJ, Rephaeli A, Nudelman A, Phillips DR et al. The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts. Cancer Chemother Pharmacol 2013; 71: 809-816.
14. Ward IM, Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem 2001; 276: 47759-47762.
15. Yajima H, Lee KJ, Chen BP. ATR-dependent phosphorylation of DNA-dependent protein kinase catalytic subunit in response to UV-induced replication stress. Mol Cell Biol 2006; 26: 7520-7528.
16. Yajima H, Lee KJ, Zhang S, Kobayashi J, Chen BP. DNA double-strand break formation upon UV-induced replication stress activates ATM and DNA-PKcs kinases. J Mol Biol 2009; 385: 800-810.
17. McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S, Pommier Y et al. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle 2010; 9: 995-1004.
18. Wang Y, Qin J. MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad Sci USA 2003; 100: 15387-15392.
19. Pabla N, Ma Z, McIlhatton MA, Fishel R, Dong Z. hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. J Biol Chem 2011; 286: 10411-10418.
20. Pors K, Patterson LH. DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents. Curr Top Med Chem 2005; 5: 1133-1149.
21. Pors K, Plumb JA, Brown R, Teesdale-Spittle P, Searcey M, Smith PJ et al. Development of nonsymmetrical 1, 4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells. J Med Chem 2005; 48: 6690-6695.
22. Sy SM, Jiang J, Dong SS, Lok GT, Wu J, Cai H et al. Critical roles of ring finger protein RNF8 in replication stress responses. J Biol Chem 2011; 286: 22355-22361.
23. Orth JD, Loewer A, Lahav G, Mitchison TJ. Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction. Mol Biol Cell 2012; 23: 567-576.
24. Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 2011; 145: 435-446.
25. Jones RM, Mortusewicz O, Afzal I, Lorvellec M, García P, Helleday T et al. Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress. Oncogene 2013; 32: 3744-3753.
26. Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999; 353: 26-29.
27. Vorechovský I, Luo L, Dyer MJ, Catovsky D, Amlot PL, Yaxley JC et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet 1997; 17: 96-99.
28. Schaffner C, Idler I, Stilgenbauer S, Döhner H, Lichter P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA 2000; 97: 2773-2778.
29. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 2013; 14: e205-e217.
30. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013; 81: 1943-1955.
31. Hof J, Krentz S, van Schewick C, Körner G, Shalapour S, Rhein P et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 3185-3193.
32. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45: 242-252.
33. Chan EY, Kir S, Tooze SA. siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy. J Biol Chem 2007; 282: 25464-25474.
34. Greaves M. Return of the malingering mutants. Br J Cancer 2013; 109: 1391-1393.
35. Redmond KM, Wilson TR, Johnston PG, Longley DB. Resistance mechanisms to cancer chemotherapy. Front Biosci 2008; 13: 5138-5154.
36. Stewart GS, Panier S, Townsend K, Al-Hakim AK, Kolas NK, Miller ES et al. The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell 2009; 136: 420-434.
37. Petermann E, Orta ML, Issaeva N, Schultz N, Helleday T. Hydroxyureastalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell 2010; 37: 492-502.